The market expects Innospec (IOSP - Free Report) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 4. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis specialty chemicals company is expected to post quarterly earnings of $1.06 per share in its upcoming report, which represents a year-over-year change of -15.9%.
Revenues are expected to be $462.35 million, up 5.2% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 2.02% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Innospec?For Innospec, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.47%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that Innospec will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Innospec would post earnings of $1.02 per share when it actually produced earnings of $1.05, delivering a surprise of +2.94%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Innospec doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAmong the stocks in the Zacks Chemical - Diversified industry, Air Products and Chemicals (APD - Free Report) , is soon expected to post earnings of $3.36 per share for the quarter ended June 2026. This estimate indicates a year-over-year change of +8.7%. This quarter's revenue is expected to be $3.18 billion, up 5.1% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Air Products and Chemicals has been revised 0.5% down to the current level. Nevertheless, the company now has an Earnings ESP of -0.51%, reflecting a lower Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), makes it difficult to conclusively predict that Air Products and Chemicals will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Investors with an interest in Chemical - Diversified stocks have likely encountered both Innospec (IOSP - Free Report) and Air Products and Chemicals (APD - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Innospec is sporting a Zacks Rank of #2 (Buy), while Air Products and Chemicals has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that IOSP has an improving earnings outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
IOSP currently has a forward P/E ratio of 17.48, while APD has a forward P/E of 22.43. We also note that IOSP has a PEG ratio of 2.33. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. APD currently has a PEG ratio of 2.69.
Another notable valuation metric for IOSP is its P/B ratio of 1.56. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, APD has a P/B of 3.64.
These metrics, and several others, help IOSP earn a Value grade of B, while APD has been given a Value grade of D.
IOSP sticks out from APD in both our Zacks Rank and Style Scores models, so value investors will likely feel that IOSP is the better option right now.
Investors looking for stocks in the Chemical - Diversified sector might want to consider either Innospec (IOSP) or Air Liquide (AIQUY). But which of these two stocks presents investors with the better value opportunity right now?
ENGLEWOOD, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced that it will release second quarter 2026 earnings results on Tuesday, August 4, 2026 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Wednesday, August 5, 2026, at 10:00 a.m. ET.
The public is invited to listen to the conference call by registering in advance using the below Online Registration Link. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique Personal PIN which can be used to join the conference 5-10 minutes prior to the start time.
Online Registration Link https://register-conf.media-server.com/register/BI9fc7c51a0e3d473bb063961a2995631c
An audio webcast of the conference call will run simultaneously on the company’s website at www.innospec.com. The relevant link as well as the slide presentation for the conference call will be found in the Investor Relations section of the website.
A replay of the webcast can also be accessed from the company’s website and will be available for 30 days following the call.
About Innospec Inc.
Innospec Inc. is an international specialty chemicals company with approximately 2,450 employees in 22 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil and gas exploration and production industry.
Forward-Looking Statements
This presentation contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends,” “outlook” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2025, Innospec’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Corbin Barnes
Innospec Inc.
+44-151-355-3611 [email protected]
ENGLEWOOD, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP), a global specialty chemicals company, has published its 2025 Sustainability Report, highlighting measurable progress across environmental performance, safety, innovation, and responsible business practices, while maintaining disciplined execution and strong cash generation.
Patrick S. Williams, President and Chief Executive Officer, said:
“Innospec continues to build a sustainable business that delivers world-class technologies and customer service in the global markets we serve. We remain focused on targeted investment and actions that drive innovation, improve efficiency, reduce environmental impact and support our customers’ priorities. We enter 2026 excited by the prospects for continued improvement in all businesses.”
Key highlights from the 2025 report include:
A 6% reduction in total employee and contractor accidents and a 96% reduction in the quantity released from loss-of-containment events.A 34% reduction in absolute Scope 1 and 2 greenhouse gas emissions since baseline year 2014, alongside a 13% reduction in Scope 3 emissions since 2022.Fuel Specialties additives delivering emissions-related benefits equivalent to 21.6 million metric tonnes of CO₂e, a 3.7% improvement from 2024.All manufacturing sites continued to procure 100% renewable electricity.Third-party verification of Innospec’s product carbon footprint (PCF) methodology assessments, covering more than 200 products across all three business units.US$51 million spent on Research and Technology in 2025, driving a 17% increase in total patent filings.A total social value of $854,000 delivered in 2025, benefiting 118 global charities and good causes local to our operations.Celebrating 10 years of the Innospec Cares program, with over $1.88 million raised and 4,864 volunteering hours contributed since its launch in 2016.$2.67 million raised for the PenFed Foundation Military Heroes program since 2007.Employees completed more than 139,000 hours of career development training, averaging 57 hours per employee. To learn more about Innospec’s sustainability programs and accomplishments, please read the 2025 Sustainability Report by visiting: https://innospecsustainability.com/2025-sustainability-report-released/
About Innospec Inc.
Innospec Inc. is an international specialty chemicals company with approximately 2,450 employees in 22 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil and gas exploration and production industry.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends,” “outlook” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2025 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Innospec is positioned as a likely beneficiary of energy shortages and rising oil prices, supplying vital chemicals for oil extraction and refining. IOSP trades at a 50% discount to sector P/E and EV/EBITDA multiples, despite a debt-free balance sheet and strong free cash flow generation. Operational catalysts include potential recovery in oilfield services, resolution of the Mexico crisis, and increased demand from geopolitical disruptions.
It has been about a month since the last earnings report for Innospec (IOSP - Free Report) . Shares have lost about 21.8% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Innospec due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Innospec Inc. before we dive into how investors and analysts have reacted as of late.
Key HighlightsEarnings per share (as reported) for the fourth quarter of 2025 improved to $1.91 from a loss of $2.80 a year ago, which was impacted by a UK pension scheme buyout.
Adjusted earnings per share rose 6% to $1.50 from $1.41 a year ago, beating the consensus mark of $1.26.
Revenues for the fourth quarter declined 2% year over year to $455.6 million, missing the Zacks Consensus Estimate of $477 million.
Adjusted EBITDA declined 2% year over year to $55.7 million. Operating income increased 14% to $46.8 million.
Segment PerformanceFuel Specialties revenues rose 1% year over year to $194.1 million, driven by volume growth of 8% offset by an adverse price/mix of 10% and a positive currency impact of 3%. Gross margin expanded 0.3 percentage points to 34.7% and operating income increased 7% to $37.2 million.
Performance Chemicals revenues were flat at $168.4 million as volume declines of 7% were offset by positive price/mix of 3% and currency of 4%. Gross margin compressed 4.6 percentage points to 18.1%, and operating income fell 14% to $17.7 million.
Oilfield Services revenues declined 12% to $93.1 million, reflecting lower U.S. completions and reduced Middle East activity. Gross margin improved 1.8 percentage points to 31.9% on richer sales mix and lower overheads and operating income increased 9% to $8.2 million.
Financials and OutlookOperating cash flow reached $61.4 million with free cash flow of $40.9 million versus $5.1 million in the year-ago quarter. The company ended 2025 with net cash of $292.5 million and no debt.
In the fourth quarter, the adjusted effective tax rate was 24.1%. The company expects a 2026 effective tax rate of roughly 26% and corporate costs of around $20 million per quarter.
Performance Chemicals’ growth is expected to be roughly flat for 2026, with margin improvement building into the second half through pricing mechanisms, manufacturing efficiencies and higher-margin new products.
For Oilfield Services, the company targets 2026 operating income growth with roughly 5-7% full-year revenue growth, led by Middle East activity and the DRA ramp. Fuel Specialties is expected to remain a stable contributor with long-term growth of 2-3%. A historic late-January 2026 winter storm is expected to impact near-term results, with Performance Chemicals' first-quarter operating income around $10-$11 million and Oilfield Services' operating income of around $5-$6 million.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -23.33% due to these changes.
VGM ScoresAt this time, Innospec has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. It's no surprise Innospec has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Allspring Global Investments Holdings LLC decreased its stake in shares of Innospec Inc. (NASDAQ:IOSP – Free Report) by 1.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,356,503 shares of the specialty chemicals company’s stock after selling 35,246 shares during the quarter. Allspring Global Investments Holdings LLC owned about 9.51% of Innospec worth $179,754,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Wedge Capital Management L L P NC lifted its position in shares of Innospec by 20.5% during the 4th quarter. Wedge Capital Management L L P NC now owns 19,699 shares of the specialty chemicals company’s stock valued at $1,508,000 after acquiring an additional 3,354 shares during the period. SG Americas Securities LLC increased its stake in Innospec by 291.0% in the fourth quarter. SG Americas Securities LLC now owns 75,814 shares of the specialty chemicals company’s stock valued at $5,803,000 after purchasing an additional 56,425 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Innospec by 37.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 178,204 shares of the specialty chemicals company’s stock valued at $13,640,000 after purchasing an additional 48,807 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Innospec by 25.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 9,223 shares of the specialty chemicals company’s stock valued at $725,000 after purchasing an additional 1,892 shares during the period. Finally, Allworth Financial LP boosted its position in shares of Innospec by 31.0% during the 3rd quarter. Allworth Financial LP now owns 588 shares of the specialty chemicals company’s stock worth $45,000 after purchasing an additional 139 shares in the last quarter. Institutional investors own 96.64% of the company’s stock.
Insiders Place Their Bets In other Innospec news, Director Larry Padfield sold 594 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $76.56, for a total value of $45,476.64. Following the transaction, the director owned 9,453 shares of the company’s stock, valued at approximately $723,721.68. The trade was a 5.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David B. Jones sold 1,028 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $75.64, for a total value of $77,757.92. Following the completion of the transaction, the senior vice president owned 14,693 shares of the company’s stock, valued at $1,111,378.52. This trade represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 4,989 shares of company stock valued at $391,889. 1.31% of the stock is owned by insiders.
Innospec Stock Performance Shares of IOSP stock opened at $73.19 on Tuesday. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of 15.64, a PEG ratio of 1.90 and a beta of 0.90. Innospec Inc. has a 52-week low of $65.51 and a 52-week high of $96.38. The company has a 50-day simple moving average of $77.77 and a two-hundred day simple moving average of $77.03.
Innospec (NASDAQ:IOSP – Get Free Report) last announced its earnings results on Tuesday, February 17th. The specialty chemicals company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.24. The firm had revenue of $455.60 million for the quarter, compared to the consensus estimate of $460.87 million. Innospec had a return on equity of 10.18% and a net margin of 6.56%.The company’s revenue was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.41 EPS. On average, sell-side analysts forecast that Innospec Inc. will post 6.18 EPS for the current fiscal year.
Analysts Set New Price Targets Several analysts have recently commented on the company. Zacks Research downgraded Innospec from a “hold” rating to a “strong sell” rating in a research note on Thursday, February 19th. Wall Street Zen upgraded Innospec from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Finally, Weiss Ratings raised Innospec from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 19th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.
View Our Latest Stock Report on Innospec
About Innospec (Free Report)
Innospec Incorporated (NASDAQ: IOSP) is a global specialty chemicals company headquartered in Cleveland, Ohio. The company operates through three principal business segments: Fuel Specialties, Oilfield Services, and Performance Chemicals. In the Fuel Specialties segment, Innospec develops and supplies additives designed to enhance octane levels, improve combustion efficiency, reduce emissions and prevent deposit formation in gasoline and diesel engines. Its Oilfield Services division provides chemical technologies—such as surfactants, corrosion inhibitors and demulsifiers—to support exploration, drilling, production optimization and enhanced oil recovery operations.
See Also Five stocks we like better than Innospec Want to see what other hedge funds are holding IOSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innospec Inc. (NASDAQ:IOSP – Free Report).
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Buys 1,099,962 Shares of Okta, Inc. $OKTA
NEXT HEADLINE »Allspring Global Investments Holdings LLC Raises Holdings in Revvity Inc. $RVTY
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Innospec (IOSP - Free Report) , which belongs to the Zacks Chemical - Diversified industry, could be a great candidate to consider.
When looking at the last two reports, this specialty chemicals company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 13.89%, on average, in the last two quarters.
For the last reported quarter, Innospec came out with earnings of $1.5 per share versus the Zacks Consensus Estimate of $1.26 per share, representing a surprise of 19.05%. For the previous quarter, the company was expected to post earnings of $1.03 per share and it actually produced earnings of $1.12 per share, delivering a surprise of 8.74%.
Price and EPS Surprise
For Innospec, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Innospec currently has an Earnings ESP of +2.46%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on May 7, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Investors in Innospec Inc. (IOSP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 18, 2026 $80 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Innospec shares, but what is the fundamental picture for the company? Currently, Innospec is a Zacks Rank #4 (Sell) in the Chemical - Diversified industry that ranks in the Bottom 34% of our Zacks Industry Rank. Over the last 30 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.04 per share to $1.02 in that period.
Given the way analysts feel about Innospec right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Zacks' 7 Best Strong Buy Stocks (New Research Report) Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
The market expects Innospec (IOSP - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis specialty chemicals company is expected to post quarterly earnings of $1.02 per share in its upcoming report, which represents a year-over-year change of -28.2%.
Revenues are expected to be $432.15 million, down 2% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 6.01% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Innospec?For Innospec, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +2.46%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Innospec will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Innospec would post earnings of $1.26 per share when it actually produced earnings of $1.50, delivering a surprise of +19.05%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Innospec doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAmong the stocks in the Zacks Chemical - Diversified industry, Albemarle (ALB - Free Report) , is soon expected to post earnings of $1.24 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +788.9%. This quarter's revenue is expected to be $1.33 billion, up 23.1% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Albemarle has been revised 18.4% up to the current level. Nevertheless, the company now has an Earnings ESP of +20.12%, reflecting a higher Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Albemarle will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Continued strength in Fuel Specialties offset negative US winter storm impacts in other businesses
Increasing confidence for sequential operating income and margin growth in Performance Chemicals and Oilfield Services
Dividend increased by 10 percent; $6.2 million in share repurchases made in the quarter
New $75 million buyback authorization
GAAP EPS of $1.22 and adjusted non-GAAP EPS of $1.05
ENGLEWOOD, Colo., May 07, 2026 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the first quarter ended March 31, 2026. The Company declared its semi-annual dividend of 92 cents per common share for the first half of this year, representing an increase of 10 percent. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.
Total revenues for the first quarter were $453.2 million, an increase of 3 percent from $440.8 million in the corresponding period last year. Net income attributable to Innospec for the quarter was $30.4 million or $1.22 per diluted share compared to $32.8 million or $1.31 per diluted share recorded in the corresponding period last year. Adjusted EBITDA for the quarter was $43.7 million compared to $54.0 million reported in the same period a year ago.
Results for this quarter include some special items, which are summarized in the table below. Excluding these items, adjusted non-GAAP EPS in the first quarter was $1.05 per diluted share, compared to $1.42 per diluted share a year ago.
Cash from operating activities was $17.6 million before capital expenditures of $8.6 million. The quarter closed with net cash of $289.1 million.
Adjusted EBITDA and net income attributable to Innospec excluding special items, and related per-share amounts, together with net cash, are non-GAAP financial measures that are defined and reconciled with GAAP results herein and in the schedules below.
Quarter ended March 31, 2026Quarter ended March 31, 2025 (in millions, except share and per share data) Net income attributable to Innospec Diluted EPS Net income attributable to Innospec Diluted EPS Reported GAAP amounts$30.4$1.22$32.8$1.31 Adjustment to fair value of contingent consideration (4.7) (0.19) 0.7 0.03 Foreign currency exchange gains (1.9) (0.08) (0.3) (0.01) Legacy costs of closed operations 1.7 0.07 0.6 0.02 Amortization of acquired intangible assets 0.8 0.03 1.7 0.07 (4.1) (0.17) 2.7 0.11 Adjusted non-GAAP amounts$26.3$1.05$35.5$1.42 Commenting on the first quarter results, Patrick S. Williams, President and Chief Executive Officer, said,
“This was a mixed quarter for Innospec with continued strong results in Fuel Specialties partially offsetting the negative impacts of the January 2026 US winter storm on Performance Chemicals and Oilfield Services.
Performance Chemicals sales were broadly flat with last year, but margins and operating income were significantly impacted by a shutdown of the North Carolina plants due to the US winter storm. We are prioritizing plant repairs in order to meet customer requirements. In parallel, we continue to execute on a range of other topline and margin opportunities identified in the business. We expect these combined efforts to drive sequential growth in the second quarter.
Fuel Specialties had another strong quarter with sales growth and margins that remained at the upper end of our target range. As expected, the business has continued to deliver consistently strong results as our team advances on a broad set of regional and end-market opportunities in traditional fuel, renewable fuel and non-fuel applications.
Oilfield Services operating income and margins improved on the prior year, but overall performance was negatively impacted by the US winter storm. While the Middle East conflict may delay the planned expansion in the region, we remain focused on driving incremental growth from our recent DRA expansion and other opportunities in our completions and production segments. We are cautiously optimistic that these efforts will drive sequential improvement in the second quarter and leave us well positioned for further improvement in the second half of 2026.”
Revenues in Performance Chemicals of $169.4 million were up 1 percent over the first quarter of last year as volume reductions of 9 percent were offset by a positive price/mix of 1 percent and favorable currency impact of 9 percent. Gross margins of 16.8 percent decreased by 4.2 percentage points from the same quarter last year. Operating income of $10.7 million decreased 46 percent from $19.8 million in the corresponding prior year period.
Revenues in Fuel Specialties of $181.6 million were up 7 percent from $170.3 million in the first quarter of last year with volume growth of 10 percent and a positive currency impact of 6 percent offsetting a negative price/mix of 9 percent. Gross margins of 35.4 percent decreased by 0.3 percentage points over last year. Operating income of $37.8 million was up 2 percent from $36.9 million a year ago.
Revenues in Oilfield Services of $102.2 million for the quarter were consistent compared with the first quarter of last year. Gross margins of 30.1 percent increased by 1.7 percentage points from the same quarter last year on a richer sales mix. Operating income of $5.6 million increased 37 percent from $4.1 million in the prior year period.
Corporate costs for the quarter were $22.3 million, compared with $17.7 million a year ago. The effective tax rate for the quarter was 22.8 percent compared to 25.7 percent in the same period last year.
For the quarter, net cash provided by operating activities was $17.6 million compared to $28.3 million a year ago. As of March 31, 2026, Innospec had $289.1 million in cash and cash equivalents and no debt.
Mr. Williams concluded,
“While the Middle East conflict is creating significant market uncertainty, we are seeing increased opportunities to deliver stand-out service and security of supply for all our customers. Our teams remain focused on elements within our control as we have in prior similar cycles. In parallel, margin enhancement, new technology commercialization and other opportunities remain the priority across our businesses, and we are optimistic about the impact that these actions will have on future results.
Operating cash generation was again positive in the quarter, and our net cash position closed at over $289 million. We have significant balance sheet flexibility for dividend growth, buybacks, organic investment and M&A. This quarter our Board approved a further 10 percent increase in our semi-annual dividend to 92 cents per share, and we completed $6.2 million in share repurchases. Additionally, the Board approved a new $75 million buyback authorization to further enhance shareholder return flexibility.”
Use of Non-GAAP Financial Measures
The information presented in this press release includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise adjusted EBITDA, net income attributable to Innospec excluding special items and related per share amounts together with net cash. Adjusted EBITDA is net income attributable to Innospec per our consolidated financial statements adjusted for the exclusion of interest income, net, income taxes, depreciation and amortization, foreign currency exchange gains, legacy costs of closed operations and adjustment to fair value of contingent consideration. Net income attributable to Innospec and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of adjustment to fair value of contingent consideration, foreign currency exchange gains, legacy costs of closed operations and amortization of acquired intangible assets. Net cash is cash and cash equivalents less total debt. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the schedules below.
The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company’s performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company’s performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and net income attributable to Innospec excluding special items and adjusted EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income attributable to Innospec) to allocate resources and evaluate the performance of the Company’s operations and has provided a reconciliation of adjusted EBITDA and net income attributable to Innospec excluding special items, and related per share amounts, to GAAP net income attributable to Innospec herein and in the schedules below.
About Innospec Inc.
Innospec Inc. is an international specialty chemicals company with approximately 2,450 employees in 22 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil and gas exploration and production industry.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends,” “outlook” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2025 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Schedule 1 Three Months Ended March 31(in millions, except share and per share data) 2026 2025 Net sales $453.2$440.8Cost of goods sold (329.7) (315.7)Gross profit 123.5 125.1 Operating expenses: Selling, general and administrative (78.5) (69.3)Research and development (13.2) (12.7)Adjustment to fair value of contingent consideration 4.7 (0.7)Profit on disposal of property, plant and equipment - 0.1Total operating expenses (87.0) (82.6)Operating income 36.5 42.5Other income, net 2.6 0.3Interest income, net 0.8 2.4Income before income taxes 39.9 45.2Income taxes (9.1) (11.6)Net income 30.8 33.6Net income attributable to non-controlling interests (0.4) (0.8)Net income attributable to Innospec $30.4$32.8 Earnings per share: Basic $1.23$1.31Diluted $1.22$1.31 Weighted average shares outstanding (in thousands): Basic 24,776 24,970Diluted 24,844 25,102 INNOSPEC INC. AND SUBSIDIARIES
Schedule 2A
SEGMENTAL ANALYSIS OF RESULTS Three Months Ended March 31(in millions) 2026 2025 Net sales: Performance Chemicals $169.4$168.4Fuel Specialties 181.6 170.3Oilfield Services 102.2 102.1 453.2 440.8 Gross profit: Performance Chemicals 28.4 35.3Fuel Specialties 64.3 60.8Oilfield Services 30.8 29.0 123.5 125.1 Operating income: Performance Chemicals 10.7 19.8Fuel Specialties 37.8 36.9Oilfield Services 5.6 4.1Corporate costs (22.3) (17.7) 31.8 43.1Adjustment to fair value of contingent consideration 4.7 (0.7)Profit on disposal of property, plant and equipment - 0.1Total operating income $36.5$42.5 Schedule 2B NON-GAAP MEASURES Three Months Ended March 31(in millions) 2026 2025 Net income attributable to Innospec $30.4$32.8Interest income, net (0.8) (2.4)Income taxes 9.1 11.6Depreciation and amortization 9.9 10.9Foreign currency exchange gains (2.5) (0.4)Legacy costs of closed operations 2.3 0.8Adjustment to fair value of contingent consideration (4.7) 0.7Adjusted EBITDA $43.7$54.0 Schedule 3INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
March 31,
2026 December 31,
2025Assets Current assets: Cash and cash equivalents $289.1$292.5Trade and other accounts receivable 354.2 342.3Inventories 321.5 329.3Prepaid expenses 16.9 20.1Prepaid income taxes 10.6 13.1Other current assets 6.8 7.3Total current assets 999.1 1,004.6 Net property, plant and equipment 285.7 286.1Operating lease right-of-use assets 50.6 52.7Goodwill 399.1 399.0Other intangible assets 68.9 67.7Deferred tax assets 13.0 13.6Other non-current assets 3.4 8.7Total assets $1,819.8$1,832.4Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $138.5$174.7Accrued liabilities 169.3 152.3Current portion of operating lease liabilities 15.1 15.9Current portion of plant closure provisions 4.9 4.9Current portion of acquisition-related contingent consideration 2.7 7.0Accrued income taxes 4.3 5.3Total current liabilities 334.8 360.1 Operating lease liabilities, net of current portion 35.5 36.8Plant closure provisions, net of current portion 60.8 60.2Deferred tax liabilities 17.9 19.1Pension liabilities and post-employment benefits 12.8 13.2Acquisition-related contingent consideration, net of current portion 1.3 1.3Other non-current liabilities 4.5 8.8Equity 1,352.2 1,332.9Total liabilities and equity $1,819.8$1,832.4 Schedule 4
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended
March 31(in millions) 2026 2025Cash Flows from Operating Activities Net income attributable to Innospec $30.4$32.8Adjustments to reconcile net income to cash provided by operating activities: Depreciation and amortization 9.9 10.9Adjustment to fair value of contingent consideration (4.7) 0.7Deferred taxes (0.7) (0.3)Profit on disposal of property, plant and equipment - (0.1)Movements on defined benefit pension plans (0.2) 1.3Stock option compensation 1.6 1.9Changes in working capital (22.3) (21.6)Movements in plant closure provisions 1.5 (0.4)Movements in income taxes 0.4 4.3Movements in other assets and liabilities 1.7 (1.2)Net cash provided by operating activities 17.6 28.3Cash Flows from Investing Activities Capital expenditures (8.9) (8.4)Proceeds on disposal of property, plant and equipment 0.3 0.1Internally developed software (5.1) (7.2)Net cash used in investing activities (13.7) (15.5)Cash Flows from Financing Activities Non-controlling interest 0.4 0.8Issue of treasury stock 0.1 0.2Repurchase of common stock (7.1) (4.8)Net cash used in financing activities (6.6) (3.8) Effect of foreign currency exchange rate changes on cash (0.7) 1.6Net change in cash and cash equivalents (3.4) 10.6Cash and cash equivalents at beginning of period 292.5 289.2Cash and cash equivalents at end of period $289.1$299.8
Innospec (IOSP - Free Report) came out with quarterly earnings of $1.05 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.42 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +3.45%. A quarter ago, it was expected that this specialty chemicals company would post earnings of $1.26 per share when it actually produced earnings of $1.5, delivering a surprise of +19.05%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Innospec, which belongs to the Zacks Chemical - Diversified industry, posted revenues of $453.2 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.87%. This compares to year-ago revenues of $440.8 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Innospec shares have added about 1.5% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for Innospec?While Innospec has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Innospec was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.10 on $457.2 million in revenues for the coming quarter and $4.96 on $1.87 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Diversified is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the broader Zacks Basic Materials sector, Sylvamo Corporation (SLVM - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 8.
This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -136.8%. The consensus EPS estimate for the quarter has been revised 4.6% higher over the last 30 days to the current level.
Sylvamo Corporation's revenues are expected to be $716 million, down 12.8% from the year-ago quarter.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 324
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Key Takeaways IOSP Q1 sales rose 3% to $453.2M, topping estimates despite lower adjusted EPS. Innospec raised its dividend 10% and announced a new $75M share repurchase plan. IOSP sees Q2 growth from plant repairs, pricing gains and Oilfield Services expansion. Innospec Inc. (IOSP - Free Report) earnings per share (as reported) for the first quarter of 2026 declined to $1.22 per share from $1.31 a year ago.
Adjusted earnings per share declined 26% to $1.05 per share from $1.42 a year ago. It beat the Zacks Consensus Estimate of $1.02 per share.
Revenues for the first quarter rose 3% year over year to $453.2 million, beating the Zacks Consensus Estimate of $432.2 million. Adjusted EBITDA declined 19% year over year to $43.7 million. Operating income declined 14% to $36.5 million.
Innospec Inc. Price, Consensus and EPS SurpriseSegment PerformanceFuel Specialties revenues rose 7% year over year to $181.6 million, driven by volume growth of 10% and a favorable currency impact of 6%, offset by an adverse price/mix of 9%. Gross margin compressed 0.3 percentage points to 35.4% and operating income increased 2% to $37.8 million.
Performance Chemicals revenues rose 1% to $169.4 million as volume declines of 9% were offset by positive price/mix of 1% and favorable currency impact of 9%. Gross margin declined 4.2 percentage points to 16.8% and operating income fell 46% to $10.7 million, adversely impacted by shutdowns at the North Carolina plants due to the January 2026 U.S. winter storm.
Oilfield Services revenues were essentially flat at $102.2 million. Gross margin improved 1.7 percentage points to 30.1% on a richer sales mix, and operating income increased 37% to $5.6 million, although results were also negatively impacted by the winter storm.
FinancialsOperating cash flow was $17.6 million versus $28.3 million in the year-ago quarter. The company ended the quarter with cash of $289.1 million and no debt.
In the first quarter, the effective tax rate was 22.8% compared with 25.7% in the year-ago quarter. The company increased its semi-annual dividend by 10% to 92 cents per share, repurchased $6.2 million of shares in the quarter and announced a new $75 million buyback authorization.
OutlookManagement expects sequential growth in the second quarter from Performance Chemicals, supported by plant repairs, pricing/mix opportunities and margin initiatives.
For Oilfield Services, the company remains cautiously optimistic that recent DRA expansion and opportunities in completions and production will drive sequential improvement in the second quarter and position the business for further improvement in the second half of 2026. Fuel Specialties is expected to remain a stable contributor, with management citing continued strength across traditional fuel, renewable fuel and non-fuel applications.
IOSP Stock’s Price PerformanceShares of Innospec have fallen 8.3% in the past year compared with the industry’s 18.7% growth.
Image Source: Zacks Investment Research
IOSP’s Zacks Rank & Key PicksIOSP currently sports a Zacks Rank #4 (Sell).
Some better-ranked stocks worth a look in the basic materials space are Sociedad Quimica y Minera de Chile S.A. (SQM - Free Report) , Idaho Strategic Resources, Inc. (IDR - Free Report) and NioCorp Developments Ltd. (NB - Free Report) .
Sociedad is slated to report first-quarter 2026 results on May 26. The Zacks Consensus Estimate for loss is pegged at $1.78 per share, indicating 270.8% year-over-year growth. SQM has a Zacks Rank #2 (Buy) at present.
Idaho is expected to report first-quarter 2026 results on May 14. The Zacks Consensus Estimate for earnings is pegged at 43 cents per share, indicating 258.3% year-over-year growth. IDR sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
NioCorp is expected to report fiscal third-quarter results on May 14. The Zacks Consensus Estimate for NB’s third-quarter loss is pegged at 2 cents per share. NB currently has a Zacks Rank #2.
